Annual Grant Award Dollars
| Investigator | Title | Sponsor | ID | Dates | Amount |
| Raouf Samy Amin, MD | Impact of Treatment of Mild Sleep-Disordered Breathing on Children’s Health-CCC | National Institutes of Health (Children's Hospital of Philadelphia) | U01 HL125295 | 07/01/2016 - 06/30/2020 | $208,190 |
| Kavisha Arora, PhD | Personalized Medicine-Elucidating Mechanism of a Novel CF Mutation | Cystic Fibrosis Foundation | ARORA16F0 | 03/01/2016 - 02/28/2018 | $65,450 |
| John J Brewington, MD | Sensitivity of Corrected F508del CFTR to Chronic Beta-agonist Therapy | Cystic Fibrosis Foundation | BREWIN16A0 | 07/01/2016 - 06/30/2019 | $130,000 |
| Lisa A Burns, MD | Transforming CF Care Through Shared Decision Making | Cystic Fibrosis Foundation (University of Cincinnati) | JOSEPH15QI0 | 01/01/2015 - 12/31/2017 | $11,031 |
| John Paul Clancy, MD | Characterizing CFTR Modulated Changes in Sweat Chloride and Clinical Outcomes | Cystic Fibrosis Fdn Therapeutics, Inc | AMIN09Y0/CLANCY14Y0 | 01/01/2013 - 12/31/2018 | $99,312 |
| John Paul Clancy, MD | CFF-TDN site | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY14K1 | 07/01/2014 - 06/30/2019 | $37,665 |
| John Paul Clancy, MD | TDC ARC Award | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY14Y4 | 12/01/2014 - 11/30/2018 | $27,012 |
| John Paul Clancy, MD | TDN Steering Committee Chair | Cystic Fibrosis Fdn Therapeutics, Inc | CLANCY16Y3 | 01/01/2016 - 12/31/2018 | $23,230 |
| John Paul Clancy, MD | Rare CFTR Mutation Cell Collection Protocol | Cystic Fibrosis Fdn Therapeutics, Inc | RARE OB-16 | 05/04/2017 - 12/31/2018 | $106,946 |
| John Paul Clancy, MD | Pilot Development of Translational Primary Human Airway Model Systems to Advance CF Care | Cystic Fibrosis Foundation | CLANCY14XX0 | 07/01/2014 - 06/30/2018 | $68,408 |
| John Paul Clancy, MD | Personalizing Cystic Fibrosis Research Translation | Cystic Fibrosis Foundation | CLANCY15R0 | 07/01/2015 - 06/30/2019 | $470,000 |
| John Paul Clancy, MD | Losartan as Anti-inflammatory Therapy to Augment F508del CFTR Recovery | Cystic Fibrosis Foundation (University of Miami) | SPC-000389 | 04/01/2017 - 09/30/2019 | $91,320 |
| John Paul Clancy, MD | Characterizing CFTR Modulated Changes in Sweat Chloride and Clinical Outcomes | Seattle Children's | Chec SC | 03/30/2018 - 03/29/2020 | $31,475 |
| Zackary Cleveland, PhD | Regional Biomarkers of Peripheral Lung Disease in Cystic Fibrosis | Cystic Fibrosis Fdn Therapeutics, Inc | CLEVEL16A0 | 04/01/2016 - 03/31/2019 | $108,000 |
| Zackary Cleveland, PhD | Time-Resolved 129Xe Ventilation-Perfusion MRI in Models of Acute Lung Injury | National Institutes of Health | R00 HL111217 | 08/15/2015 - 07/31/2018 | $236,446 |
| Daniel Grossoehme, D.Min. | Training Research-Literate Chaplains as Ambassadors for Spirituality and Health | John Templeton Foundation (Rush Medical University Center) | 51996 | 07/01/2015 - 06/30/2019 | $9,163 |
| Theresa Guilbert, MD, MS | Controlling and Preventing Asthma Progression and Severity in Kids (CASK) | National Institutes of Health (Children's Hospital Boston) | U01 AI126614 | 04/01/2017 - 06/30/2018 | $110,000 |
| Theresa Guilbert, MD, MS | ORBEX: Primary Prevention of Asthma and Wheezing in Children | National Institutes of Health (University of Arizona) | PO 438886 | 02/01/2018 - 04/30/2021 | $45,499 |
| William D Hardie, MD John Paul Clancy, MD |
Cincinnati Children's Summer Medical Student Respiratory Research Fellowship | National Institutes of Health | T35 HL113229 | 05/01/2016 - 04/30/2021 | $70,632 |
| Yunjie Huang, PhD | Targeting ERdj4, a Novel Co-chaperone in the ER Lumen, to Rescue Mutant CFTR | Cystic Fibrosis Foundation | HUANG17F0 | 04/01/2017 - 03/31/2019 | $63,100 |
| Elizabeth L Kramer, MD, PhD | The Role of TGF? in Driving Airway Hyperresponsiveness and Smooth Muscle Dysfunction in Cystic Fibrosis | Cystic Fibrosis Research, Inc. | Cystic Fib - Kramer, | 06/01/2018 - 05/31/2020 | $69,029 |
| Satish K Madala, PhD | Therapeutic Benefit of Hsp90 Inhibition in Pulmonary Fibrosis | Department of Defense Army | W81XWH-17-1-0666 | 09/30/2017 - 09/29/2020 | $575,615 |
| Satish K Madala, PhD Anil G. Jegga, DVM |
Integrative Analysis of Multi-omics Data to Target Fibroblast Activation in IPF | National Institutes of Health | R21 HL133539 | 07/05/2016 - 06/30/2018 | $60,314 |
| Satish K Madala, PhD | WT1 Regulation of Pulmonary Fibrosis | National Institutes of Health | R01 HL134801 | 05/22/2017 - 04/30/2022 | $395,371 |
| Gary McPhail, MD | Cystic Fibrosis Center Program Accreditation And Funding | Cystic Fibrosis Foundation | CC160-130 | 07/01/2013 - 06/30/2018 | $143,810 |
| Gary McPhail, MD | Implementation of the Depression & Anxiety Guidelines | Cystic Fibrosis Foundation | CMHC160-15 | 01/01/2016 - 12/31/2018 | $108,243 |
| Anjaparavanda Naren, PhD | CF-Patient Specific Enteroids from Small Intestine and Colon | Cystic Fibrosis Fdn Therapeutics, Inc | NAREN14XX0 | 07/01/2014 - 06/30/2018 | $226,492 |
| Anjaparavanda Naren, PhD | Human Small Intestinal Model from CF-Patients using Pluripotent Stem Cells | Cystic Fibrosis Foundation | NAREN16I0 | 04/01/2016 - 03/31/2018 | $54,000 |
| Anjaparavanda Naren, PhD | LPA2 Receptor-containing Complexes in Regulating Secretory Diarrhea | National Institutes of Health | R01 DK093045 | 07/01/2015 - 06/30/2020 | $351,000 |
| Anjaparavanda Naren, PhD | Human Enteroids, Colonoids, and iPSC derived HIO's to study CFTR-related Disorders | National Institutes of Health | R56 DK112321 | 09/20/2017 - 08/31/2022 | $102,448 |
| Anjaparavanda Naren, PhD | Transporters and Hematopoietic Toxicity | National Institutes of Health (St Jude's Children's Hospital) | R01 CA194206 | 07/01/2016 - 06/30/2021 | $28,595 |
| Anjaparavanda Naren, PhD | Characterization of an Inhibitory Protein Complex for Cystic Fibrosis Therapy | National Institutes of Health (Univ of Tennessee Health Science Center) | HL 123535 CCHMC | 08/15/2014 - 06/30/2019 | $18,082 |
| Michael Seid, PhD | A CF C3N Care Model of the Future: Proposal for Piloting a Learning Health System | Cystic Fibrosis Fdn Therapeutics, Inc | SEID15A0 | 01/01/2016 - 12/31/2018 | $2,708,097 |
| Michael Seid, PhD | FL3X: An Adaptive Intervention to Improve Outcomes for Youth with Type 1 Diabetes | National Institutes of Health (University of North Carolina) | UC4 DK101132 | 09/15/2013 - 06/30/2018 | $399,136 |
| Michael Seid, PhD | Healthy Mind Healthy You: A Dose-Finding Study of Mindfulness | Patient-Centered Outcome Research Inst. (Massachusetts General Hospital) | Nierenberg/Massachus | 08/01/2016 - 07/31/2019 | $81,988 |
| Michael Seid, PhD | Measures of Hypoglycemia and Glycemic Variability Using Continuous Glucose Monitoring in the FL3X Intervention for Youth With Type 1 Diabetes | The Leona M & Harry B Helmsley Charitabl (University of North Carolina) | 2014PG-T1D030 | 01/01/2014 - 12/31/2017 | $10,000 |
| Christopher Siracusa, MD | CFF Success with Therapies Research Consortium - Cincinnati Children's | Cystic Fibrosis Fdn Therapeutics, Inc | SIRACU15PE0 | 08/01/2016 - 07/31/2018 | $30,240 |
| Christopher Siracusa, MD | Development of Standardized Measures of Barriers to Treatment Adherence: Field Testing and Psychometric Validation | Cystic Fibrosis Fdn Therapeutics, Inc (Children's Hospital Boston) | CHB - Siracusa,Chris | 08/01/2017 - 12/31/2018 | $14,365 |
| Ina St Onge, DO | 1st Year Training Grant | Cystic Fibrosis Foundation | STONGE17B0 | 07/01/2017 - 06/30/2019 | $61,250 |
| Laura L Walkup, PhD | Early Detection of Regional BOS in BMT Patients using UTE and 129Xe MRI | National Institutes of Health | K99 HL138255 | 09/01/2017 - 08/31/2019 | $111,035 |
| Jason C Woods, PhD John Paul Clancy, MD |
UTE MRI to Monitor CF Lung Disease and Response to CFTR Modulation in Young Children | National Institutes of Health | R01 HL131012 | 05/01/2016 - 03/31/2021 | $736,259 |
| Jason C Woods, PhD | A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease | National Institutes of Health (Polarean Inc.) | R44 HL123299 | 04/15/2017 - 03/31/2020 | $441,219 |
| Jason C Woods, PhD | Molecular Pathogenesis and Treatment of Pulmonary Alveolar Microlithiasis | National Institutes of Health (University of Cincinnati) | 009628-005 | 04/01/2015 - 03/31/2020 | $44,503 |
| Assem Ziady, PhD | Full Analysis of the CF Serum Proteome | Cystic Fibrosis Fdn Therapeutics, Inc | ZIADY17XX0 | 01/01/2017 - 12/31/2017 | $36,247 |
| Assem Ziady, PhD | Stop Ototoxicity | Cystic Fibrosis Fdn Therapeutics, Inc (Sound Pharmaceuticals, Inc.) | SDI - Ziady,Assem | 10/05/2017 - 10/04/2018 | $57,137 |
| Assem Ziady, PhD | Manipulating Vector Interactome to Enhance Gene Transfer in Cystic Fibrosis | Cystic Fibrosis Foundation | ZIADY1610 | 11/01/2016 - 10/31/2018 | $54,000 |
| Assem Ziady, PhD | Longitudinal Study of Cystic Fibrosis Liver Disease | Cystic Fibrosis Foundation (University of Colorado) | NARKEW16AB0 | 01/01/2017 - 12/31/2018 | $82,190 |
| Assem Ziady, PhD John Paul Clancy, MD |
Targeting Vector Interactome to Enhance CFTR Delivery | National Institutes of Health | R21 EB023800 | 09/30/2017 - 07/31/2019 | $238,500 |
| Assem Ziady, PhD | Validating Biomarker Based Predictive Algorithms for Lung Disease Progression in Cystic Fibrosis | National Institutes of Health (Cleveland Clin Lerner Col of Med of CWRU) | U54 HL119810 | 08/01/2017 - 07/31/2018 | $108,300 |
| Total Annual Grant Award Dollars | $9,360,344 | ||||
Annual Industry Award Dollars
| Investigator | Industry Sponsor | Amount |
| Lisa A Burns, MD | Vertex Pharmaceutical Incorporated | $50,000 |
| John Paul Clancy, MD | Savara Pharmaceuticals | $75,719 |
| Sheharyar Durrani, MD | Sanofi Pasteur Biologics, LLC | $304,761 |
| Gary McPhail, MD | Vertex Pharmaceutical Incorporated | $165,538 |
| Anjaparavanda Naren, PHD | Ironwood Pharmaceuticals, Inc. | $200,000 |
| Jason C Woods, PHD | Genentech, Inc. | $4,000 |
| Jason C Woods, PHD | Grifols, Inc | $168,174 |
| Jason C Woods, PHD | Vertex Pharmaceutical Incorporated | $91,495 |
| Total Annual Industry Award Dollars | $1,059,687 | |
